Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    April 2018
  1. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Text format     Abstract available


  2. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Text format     Abstract available


  3. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Text format     Abstract available


    January 2018
  4. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    PubMed     Text format     Abstract available


    November 2017
  5. TIMMERMANS M, Sonke GS, Van de Vijver KK, van der Aa MA, et al
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
    Eur J Cancer. 2017;88:31-37.
    PubMed     Text format     Abstract available


  6. TEMKIN SM, Miller EA, Samimi G, Berg CD, et al
    Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Eur J Cancer. 2017;87:182-188.
    PubMed     Text format     Abstract available


  7. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Text format     Abstract available


    October 2017
  8. VERSLUIS MAC, Marchal S, Plat A, de Bock GH, et al
    The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Eur J Cancer. 2017;86:285-295.
    PubMed     Text format     Abstract available


  9. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Text format     Abstract available


    September 2017
  10. VANDERSTICHELE A, Busschaert P, Olbrecht S, Lambrechts D, et al
    Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2017;86:5-14.
    PubMed     Text format     Abstract available


    August 2017
  11. EGGINK FA, Mom CH, Bouwman K, Boll D, et al
    Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].
    Eur J Cancer. 2017 Aug 22. pii: S0959-8049(17)31186.
    PubMed     Text format    


  12. LEE YC, Milne RL, Lheureux S, Friedlander M, et al
    Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
    Eur J Cancer. 2017;84:114-120.
    PubMed     Text format     Abstract available


  13. SIMIN J, Tamimi R, Lagergren J, Adami HO, et al
    Menopausal hormone therapy and cancer risk: An overestimated risk?
    Eur J Cancer. 2017;84:60-68.
    PubMed     Text format     Abstract available


    July 2017
  14. VERGOTE IB, Smith DC, Berger R, Kurzrock R, et al
    A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
    Eur J Cancer. 2017;83:229-236.
    PubMed     Text format     Abstract available


  15. MICHIELSEN K, Dresen R, Vanslembrouck R, De Keyzer F, et al
    Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer.
    Eur J Cancer. 2017;83:88-98.
    PubMed     Text format     Abstract available


    June 2017
  16. HONG N, Yoon HG, Seo DH, Park S, et al
    Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Eur J Cancer. 2017;82:103-114.
    PubMed     Text format     Abstract available


  17. MIRGHANI H, Jung AC, Fakhry C
    Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers.
    Eur J Cancer. 2017;78:105-115.
    PubMed     Text format     Abstract available


    May 2017
  18. MARLOW LAV, Chorley AJ, Haddrell J, Ferrer R, et al
    Understanding the heterogeneity of cervical cancer screening non-participants: Data from a national sample of British women.
    Eur J Cancer. 2017;80:30-38.
    PubMed     Text format     Abstract available


  19. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTI
    Eur J Cancer. 2017;79:214-225.
    PubMed     Text format     Abstract available


    April 2017
  20. SALEHI S, Avall-Lundqvist E, Legerstam B, Carlson JW, et al
    Robot-assisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer: A randomised controlled trial.
    Eur J Cancer. 2017;79:81-89.
    PubMed     Text format     Abstract available


  21. JOLY F, Hilpert F, Okamoto A, Stuart G, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
    Eur J Cancer. 2017;78:133-138.
    PubMed     Text format     Abstract available


  22. EGGINK FA, Mom CH, Bouwman K, Boll D, et al
    Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.
    Eur J Cancer. 2017;78:82-90.
    PubMed     Text format     Abstract available


    March 2017
  23. GEORGE A, Kristeleit R, Rafii S, Michie CO, et al
    Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    Eur J Cancer. 2017;76:52-59.
    PubMed     Text format     Abstract available


  24. LYNGE E, Lonnberg S, Tornberg S
    Cervical cancer incidence in elderly women-biology or screening history?
    Eur J Cancer. 2017;74:82-88.
    PubMed     Text format     Abstract available


    February 2017
  25. AMBATIPUDI S, Horvath S, Perrier F, Cuenin C, et al
    DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility.
    Eur J Cancer. 2017;75:299-307.
    PubMed     Text format     Abstract available


    January 2017
  26. HOCKEL M, Wolf B, Hentschel B, Horn LC, et al
    Surgical treatment and histopathological assessment of advanced cervicovaginal carcinoma: A prospective study and retrospective analysis.
    Eur J Cancer. 2017;70:99-110.
    PubMed     Text format     Abstract available


    December 2016
  27. DE JONGE MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, et al
    Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
    Eur J Cancer. 2016;72:215-225.
    PubMed     Text format     Abstract available


  28. LAMBERTINI M, Cinquini M, Moschetti I, Peccatori FA, et al
    Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
    Eur J Cancer. 2016;71:25-33.
    PubMed     Text format     Abstract available


    November 2016
  29. ROUZIER R, Gouy S, Selle F, Lambaudie E, et al
    Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
    Eur J Cancer. 2016;70:133-142.
    PubMed     Text format     Abstract available


  30. MARTH C, Vergote I, Scambia G, Oberaigner W, et al
    ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    Eur J Cancer. 2016;70:111-121.
    PubMed     Text format     Abstract available


  31. VERGOTE I, Banerjee S, Gerdes AM, van Asperen C, et al
    Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Eur J Cancer. 2016;69:127-134.
    PubMed     Text format     Abstract available


  32. JEPPESEN MM, Jensen PT, Gilsa Hansen D, Iachina M, et al
    The nature of early-stage endometrial cancer recurrence-A national cohort study.
    Eur J Cancer. 2016;69:51-60.
    PubMed     Text format     Abstract available


    September 2016
  33. ABDEL-QADIR H, Amir E, Fischer HD, Fu L, et al
    The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Eur J Cancer. 2016;68:11-21.
    PubMed     Text format     Abstract available


  34. HUANG KC, Yang J, Ng MC, Ng SK, et al
    Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
    Eur J Cancer. 2016;67:152-163.
    PubMed     Text format     Abstract available


    August 2016
  35. NAGRANI R, Mhatre S, Rajaraman P, Soerjomataram I, et al
    Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity.
    Eur J Cancer. 2016;66:153-161.
    PubMed     Text format     Abstract available


  36. KLAR M, Hasenburg A, Hasanov M, Hilpert F, et al
    Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
    Eur J Cancer. 2016;66:114-124.
    PubMed     Text format     Abstract available


  37. KLEPPE M, van der Aa MA, Van Gorp T, Slangen BF, et al
    The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer.
    Eur J Cancer. 2016;66:83-90.
    PubMed     Text format     Abstract available


  38. KOSKAS M, Jozwiak M, Fournier M, Vergote I, et al
    Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer.
    Eur J Cancer. 2016;65:185-191.
    PubMed     Text format     Abstract available


  39. VAN DER STEEN-BANASIK E, Christiaens M, Shash E, Coens C, et al
    Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma.
    Eur J Cancer. 2016;65:172-181.
    PubMed     Text format     Abstract available


    July 2016
  40. DU BOIS A, Ewald-Riegler N, de Gregorio N, Reuss A, et al
    Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynakologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].
    Eur J Cancer. 2016 Jul 25. pii: S0959-8049(16)32278.
    PubMed     Text format    


  41. LEMETRE C, Vieites B, Ng CK, Piscuoglio S, et al
    RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
    Eur J Cancer. 2016;64:149-158.
    PubMed     Text format     Abstract available


    June 2016
  42. ONDA T, Satoh T, Saito T, Kasamatsu T, et al
    Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncolog
    Eur J Cancer. 2016;64:22-31.
    PubMed     Text format     Abstract available


  43. PALMA-ARDILES G, Hernandez-Fernandez W, Gianuzzi X, Hernandez AV, et al
    Letter to the Editor regarding the paper by Sang-Hee Yoon et al., Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis.
    Eur J Cancer. 2016 Jun 15. pii: S0959-8049(16)32166.
    PubMed     Text format    


    May 2016
  44. ARTS-DE JONG M, de Bock GH, van Asperen CJ, Mourits MJ, et al
    Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Eur J Cancer. 2016;61:137-145.
    PubMed     Text format     Abstract available


  45. KOSKAS M, Fournier M, Vanderstraeten A, Walker F, et al
    Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study.
    Eur J Cancer. 2016;61:52-60.
    PubMed     Text format     Abstract available


  46. PAOLINI F, Curzio G, Melucci E, Terrenato I, et al
    Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions.
    Eur J Cancer. 2016;58:52-61.
    PubMed     Text format     Abstract available


    April 2016
  47. AMMOTHUMKANDY A, Maliekal TT, Bose MV, Rajkumar T, et al
    CD66 and CD49f expressing cells are associated with distinct neoplastic phenotypes and progression in human cervical cancer.
    Eur J Cancer. 2016;60:166-178.
    PubMed     Text format     Abstract available


    March 2016
  48. PANT S, Jones SF, Kurkjian CD, Infante JR, et al
    A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
    Eur J Cancer. 2016;56:1-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: